PMN331
Parkinson's Disease / Multiple System Atrophy
PreclinicalActive
Key Facts
Indication
Parkinson's Disease / Multiple System Atrophy
Phase
Preclinical
Status
Active
Company
About ProMIS Neurosciences
ProMIS Neurosciences is dedicated to developing precision antibody therapies for neurodegenerative diseases by selectively targeting toxic misfolded protein oligomers. Its core achievement is the EpiSelect™ computational discovery platform, which has generated a pipeline of candidates, including PMN310 for Alzheimer's disease, now in a Phase 1b trial. The company's strategy is to demonstrate a differentiated safety and efficacy profile by sparing non-toxic protein forms, aiming to advance directly into registrational studies. A recent $175 million financing provides a cash runway through 2027 to execute this plan.
View full company profile